research reports and media, page-3630

All of this seems to be linked to examining Elmiron in clinical trials and to also potentially help with NHMRC funding perhaps, since no company will want to fund OA trials with Elmiron due to the safety issues, lack of bio availability and the absence of meaningful IP. So my guess is the timing of the publications are the result of NHMRC applications to help fund the clinical trials.

This is on the back of the following article shared by Iken, which shows when you consider a historical control for OA that Elmiron doesn't work based on their treatment protocol: https://www.sciencedirect.com/science/article/pii/S2665913123000109

The following trial was registered two years ago, which it seems they have yet to find funding for:https://trialsearch.who.int/?TrialID=ACTRN12621000654853

Arthropharm have an interest presumably because they would supply Elmiron. I note in the review article that they mention NGF, but fail to provide a reference. Maybe they were referring to the following: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0222602.